Evidence map›Paper›PMID 27683633›Full record

ReviewWorld journal of transplantation2016

Current techniques for AB0-incompatible living donor liver transplantation.

Silke Rummler, Astrid Bauschke, Erik Bärthel, Heike Jütte, Katrin Maier, Patrice Ziehm, Christina Malessa, Utz Settmacher

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Tolerogenic Therapies in Cardiac Transplantation.International journal of molecular sciences · 2025
    Review
  4. Article
  5. [Clinical Analysis of ABO-Incompatible Living-Donor Liver Transplantation in Children].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022
    Article
  6. Article
  7. Article
  8. Lessons learnt from living donor liver transplantation with ABO-incompatibility: A single-centre experience from southern India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019
    Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silke RummlerSilke Rummler, Heike Jütte, Katrin Maier, Patrice Ziehm, Institute of Transfusion Medicine, University Hospital Jena, 07747 Jena, Germany.
Astrid BauschkeSilke Rummler, Heike Jütte, Katrin Maier, Patrice Ziehm, Institute of Transfusion Medicine, University Hospital Jena, 07747 Jena, Germany.
Erik BärthelSilke Rummler, Heike Jütte, Katrin Maier, Patrice Ziehm, Institute of Transfusion Medicine, University Hospital Jena, 07747 Jena, Germany.
Heike JütteSilke Rummler, Heike Jütte, Katrin Maier, Patrice Ziehm, Institute of Transfusion Medicine, University Hospital Jena, 07747 Jena, Germany.
Katrin MaierSilke Rummler, Heike Jütte, Katrin Maier, Patrice Ziehm, Institute of Transfusion Medicine, University Hospital Jena, 07747 Jena, Germany.
Patrice ZiehmSilke Rummler, Heike Jütte, Katrin Maier, Patrice Ziehm, Institute of Transfusion Medicine, University Hospital Jena, 07747 Jena, Germany.
Christina MalessaSilke Rummler, Heike Jütte, Katrin Maier, Patrice Ziehm, Institute of Transfusion Medicine, University Hospital Jena, 07747 Jena, Germany.
Utz SettmacherSilke Rummler, Heike Jütte, Katrin Maier, Patrice Ziehm, Institute of Transfusion Medicine, University Hospital Jena, 07747 Jena, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For a long time, it was considered medical malpractice to neglect the blood group system during transplantation. Because there are far more patients waiting for organs than organs available, a variety of attempts have been made to transplant AB0-incompatible (AB0i) grafts. Improvements in AB0i graft survival rates have been achieved with immunosuppression regimens and plasma treatment procedures. Nevertheless, some grafts are rejected early after AB0i living donor liver transplantation (LDLT) due to antibody mediated rejection or later biliary complications that affect the quality of life. Therefore, the AB0i LDLT is an option only for emergency situations, and it requires careful planning. This review compares the treatment possibilities and their effect on the patients' graft outcome from 2010 to the present. We compared 11 transplant center regimens and their outcomes. The best improvement, next to plasma treatment procedures, has been reached with the prophylactic use of rituximab more than one week before AB0i LDLT. Unfortunately, no standardized treatment protocols are available. Each center treats its patients with its own scheme. Nevertheless, the transplant results are homogeneous. Due to refined treatment strategies, AB0i LDLT is a feasible option today and almost free of severe complications.

Indexed as

AB0-incompatibleBiliary complicationsDesensitizationIso-titerLiving-donor liver transplantationRituximab

Identifiers

PMID27683633
PMCPMC5036124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.